Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT Number: NCT00105456
This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.
Looking for future studies?
Notify MeAll sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Genentech, Inc.
Industry
registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00043472
Adnexal Diseases, Breast Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsNCT00006421
Breast Cancer, Breast Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT02206984
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial Details